Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571).
Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be considered in high risk groups. We report a case of TLS in a patient with metastatic gastrointestinal stromal tumour treated with imatinib mesylate. To our knowledge, this is the first reported case.
Pinder
Elizabeth M
EM
Department of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
Atwal
Gurprit S S
GS
Ayantunde
Abraham A
AA
Khan
Sarah
S
Sokal
Mike
M
McCulloch
Tom
T
Parsons
Simon L
SL